EBV binds to lymphocytes of transgenic mice that express the human CR2 gene

Virus Research

Volumn 50, Issue 1, 1997, Pages 85-94

  Kearns Jonker, Mary ^a   Monell Torrens, Esteban ^a   Abbasi, Fatima ^a   Michael Holers, V ^b   Louis Notkins, Abner ^a   Sigounas, George ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Epstein Barr virus; Human CR2; Lymphocytes; Transgenic mouse

Indexed keywords

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN CELL; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRUS CELL INTERACTION;

ANIMALS; CELL LINE; GENE EXPRESSION; GENETIC VECTORS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTES; MICE; MICE, TRANSGENIC; RECEPTORS, COMPLEMENT 3D; RECEPTORS, VIRUS; TRANSGENES; TUMOR VIRUS INFECTIONS;

ANIMALIA; HUMAN HERPESVIRUS 4; MUS MUSCULUS;

EID: 0030788669     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(97)00052-X     Document Type: Article

References (33)

1. Ahearn J.M., Hayward S.D., Hickey J.C., Fearon D.T. Epstein-Barr virus (EBV) infection of murine L-cells expressing recombinant human EBV/C3d receptor. Proc. Natl. Acad. Sci. USA. 85:1988;9307-9311.
2. Aquino A., Lisi A., Pozzi D., Ravagnan G., Grimaldi S. EBV membrane receptor (CR2) is phosphorylated by protein kinase C (PKC) in the early stages of virus entry into lymphoblastoid cell line (Raji). Biochem. Biophys. Res. Comm. 196:1993;794-802.
3. Cantaloube J.F., Piechaczyk M., Calender A., Lenoir G., Minty A., Carriere D., Fischer E., Poncelet P. Stable expression and function of EBV/C3d receptor following genomic transfection into murine fibroblast L-cells. Eur. J. Immunol. 20:1990;409-416.
4. Carel J.C., Myones B.L., Frazier B., Holers V.M. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization and viral infection. J. Biol. Chem. 265:1990;12293-12299.
5. Carel J.C., Frazier B., Ley T.J., Holers V.M. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells. J. Immunol. 143:1989;923-930.
6. Cooper N.R., Moore M.D., Nemerow G.R. Immunobiology of CR2, the B-lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Ann. Rev. Immunol. 6:1988;85-113.
7. Delcayme A.X., Salas F., Mathur S., Kovats K., Lotz M., Lernhardt W. Epstein-Barr virus/complement C3d receptor is an interferon α receptor. EMBO. 10:1991;919-926.
8. Fields A.P., Bednarik D.P., Hess A., May W.S. Human immunodeficiency virus induces phosphorylation of its cell surface receptor. Nature. 333:1988;278-280.
9. Fingeroth J.D., Benedict M.A., Levy D.N., Strominger J.L. Identification of murine complement receptor type 2. Proc. Natl. Acad. Sci. USA. 86:1989;242-246.
10. Fingeroth J.D., Clabby M.L., Strominger J.D. Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21). J. Virol. 62:1988;1442-1447.
11. Fingeroth J.D., Weis J.J., Tedder T.F., Strominger J.L., Biro P.A., Fearon D.T. Epstein-Barr virus receptor of human B-lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA. 81:1984;4510-4514.
12. Fischer E., Delibrias C., Kazatchkine M.D. Expression of CR2 (the C3d,g/EBV receptor, CD21) on normal human peripheral blood T-lymphocytes. J. Immunol. 146:1991;865-869.
13. Fujisaku A., Harley J.B., Frank M.B., Gruner B.A., Frazier B., Holers V.M. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. J. Biol. Chem. 264:1989;2118-2125.
14. Graessmann A., Wolf H., Bornkamm G.W. Expression of Epstein-Barr virus genes in different cell types after microinjection of viral DNA. Proc. Natl. Acad. Sci. USA. 77:1980;433-436.
15. Hogan, B., Constantini, F., Lacy, E., 1986. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
16. Iida K., Nadler L., Nussenzweig V. Identification of the membrane fragment for the complement fragment C3d by means of a monoclonal antibody. J. Exp. Med. 158:1983;1021-1033.
17. Inghirami G., Nakamura M., Balow J.E., Notkins A.L., Casali P. Model for studying virus attachment: Identification and quantitation of Epstein-Barr virus-binding cells by using biotinylated virus in flow cytometry. J. Virol. 62:1988;2453-2463.
18. Ley T.J., Anagnou N.P., Pepe G., Nienhuis A.W. RNA processing errors in patients with B-thalassemia. Proc. Natl. Acad. Sci. USA. 22:1982;4775-4779.
19. Li Q.X., Young L.S., Niedobitek G., Dawson C.W., Birkenbach M., Wang F., Rickinson A.B. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature. 356:1992;347-350.
20. Lindhout E., Lakeman A., Mevissen M.L., deGroot C. Functionally active Epstein-Barr virus-transformed follicular dendritic cell-like cell lines. J. Exp. Med. 179:1994;1173-1184.
21. Lowell C.A., Klickstein L.B., Carter R.H., Mitchell J.A., Fearon D.T., Ahearn J.M. Mapping of the Epstein-Barr virus and C3d,g binding sites to a common domain on complement receptor type 2. J. Exp. Med. 170:1989;1931-1946.
22. Martin D.R., Yuryeu A., Kalli K.R., Fearon D.T., Ahearn J.M. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement. J. Exp. Med. 174:1991;1299-1311.
23. Martin D.R., Marlowe R.L., Ahearn J.M. Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells. J. Virol. 68:1994;4716-4726.
24. Matsumoto A.K., Kopicky-Burd J., Carter R.H., Tuveson D.A., Tedder T.F., Fearon D.T. Intersection of the complement and immune systems: A signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J. Exp. Med. 173:1991;55-64.
25. Mittler R., Talle M., Carpenter K., Rao P., Goldstein G. Generation and characterization of monoclonal antibodies reactive with human B-lymphocytes. J. Immunol. 131:1983;1754-1761.
26. Molina H., Bremer C., Jacobi S., Gorko J., Carel J.C., Kinoshita T., Holers V.M. Analysis of Epstein Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. J. Biol. Chem. 266:1991;12173-12179.
27. Moore M.D., Cooper N.R., Tack B.F., Nemerow G.R. Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B-lymphocytes. Proc. Natl. Acad. Sci. USA. 84:1987;9194-9198.
28. Nemerow G.R., Cooper N.R. Early events in the infection of human B-lymphocytes by Epstein-Barr virus: The internalization process. Virology. 132:1984;186-198.
29. Reynes M., Aubert J.P., Cohen J.H., Audouin J., Tricottet V., Diebold J., Kazatchkine M.D. Human follicular dendritic cells expressed CR1, CR2 and CR3 complement receptor antigens. J. Immunol. 135:1985;1687-2694.
30. Tuveson D.A., Ahearn J.M., Matsumoto A.K., Fearon D.T. Molecular interactions of complement receptors on B lymphocytes: A CR1/CR2 complex distinct from the CR2/CD19 complex. J. Exp. Med. 173:1991;1083-1089.
31. Volsky D.J., Shapiro I.M., Klein G. Transfer of Epstein-Barr virus receptors to receptor-negative cells permits virus penetration and antigen expression. Proc. Natl. Acad. Sci. USA. 77:1980;5453-5457.
32. r membrane protein as the CR2 receptor (CR2) of human B-lymphocytes. Proc. Natl. Acad. Sci. USA. 81:1984;881-885.
33. Young L.S., Clark D., Sixbey J.W., Rickinson A.B. Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet. 1:1986;240-242.